Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Burning sensation, Condition aggravated, Discomfort, Erythema
Clinical narrative: rash trunk; face red; fever; Worsened; Eyelid rash; Burning sensation in face; Swelling of face; Urticaria localized; pain in face; discomfort/Face was stretched to limit and really hurt, Uncomfortable; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4429208-00.  A 44-year-old female patient received BNT162b2 (BNT162B2), on 29Apr2022 as dose 3 (booster), single (Lot number: FK9894) at the age of 44 years intramuscular for covid-19 immunisation; adalimumab (HUMIRA), on 04May2022 (Batch/Lot number: unknown) subcutaneous for rheumatoid arthritis, ankylosing spondylitis; diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (TDAP), on 29Apr2022 as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history included: "Ankylosing Spondylitis" (unspecified if ongoing); "Epilepsy" (unspecified if ongoing); "Rheumatoid Arthritis" (unspecified if ongoing); "Gerd" (unspecified if ongoing); "Interstitial Cystitis" (unspecified if ongoing); "Restless Leg" (unspecified if ongoing). Concomitant medication(s) included: PREGABALIN; ESTRADIOL; KEPPRA [LEVETIRACETAM]; PLAQUENIL [HYDROXYCHLOROQUINE SULFATE]; ZYRTEC [CETIRIZINE HYDROCHLORIDE]; CLARITIN [LORATADINE]; TAGAMET [CIMETIDINE]; PHENOXYMETHYLPENICILLIN POTASSIUM. Past drug history included: Levofloxacin, reaction(s): "Levofloxacin Allergy"; Diltiazem, reaction(s): "Diltiazem allergy"; Furosemide, reaction(s): "Furosemide Allergy". Vaccination history included: comirnaty (dose 1, lot no.EW0151, Intramuscular), administration date: 05Apr2021, for covid-19 immunization; comirnaty (dose 2, lot no. EA6207, Intramuscular), administration date: 15Mar2022, for covid-19 immunization; Zoster vaccine recombinant adjuvanted, reaction(s): "Zoster Vaccine Recombinant Adjuvanted Allergy". The following information was reported: BURNING SENSATION (non-serious) with onset 05May2022, outcome "not recovered", described as "Burning sensation in face"; EYELID RASH (non-serious) with onset 05May2022, outcome "not recovered"; SWELLING FACE (non-serious) with onset 05May2022, outcome "not recovered", described as "Swelling of face"; URTICARIA (non-serious) with onset 05May2022, outcome "not recovered", described as "Urticaria localized"; DISCOMFORT (non-serious) with onset 05May2022, outcome "not recovered", described as "discomfort/Face was stretched to limit and really hurt, Uncomfortable"; FACIAL PAIN (non-serious) with onset 05May2022, outcome "not recovered", described as "pain in face"; RASH (non-serious), outcome "unknown", described as "rash trunk"; ERYTHEMA (non-serious), outcome "not recovered", described as "face red"; PYREXIA (non-serious), outcome "unknown", described as "fever"; CONDITION AGGRAVATED (non-serious), outcome "unknown", described as "Worsened". Relevant laboratory tests and procedures are available in the appropriate section. The action taken for adalimumab was unknown.   Follow-up attempts are completed. No further information is expected.